Abstract 1413
Background
Although recent advances in high-throughput technology have provided many insights into gastric cancer (GC), few reliable biomarkers for handling diffuse type GC are identified. Here, we aim to identify a prognostic and predictive signature predicting heterogeneous clinical courses of diffuse type GC.
Methods
We analysed RNA-seq based transcriptome data to identify a molecular signature in 150 gastric tissue samples including 107 diffuse type GCs. The predictive value of the signature was verified using other diffuse type GCs in three independent cohorts (n = 466). Various statistical methods, including log-rank and Cox regression analyses, were used to estimate an association between the signature and prognosis. The signature was also characterized by somatic variant assessments and tissue microarray analysis between diffuse type GC subtypes.
Results
Transcriptomic profiling revealed two distinct subtypes of diffuse type GC including intestinal-like (INT) and core diffuse type (COD) subgroups. We generated a signature, namely COD-signature, reflecting the best characteristics of subtypes. When estimating prognostic value in other cohorts, COD-signature showed a strong predictability and an independent clinical utility in diffuse type GC prognosis (hazard ratio = 2.058, 95% confidence interval = 1.53-2.77, P < 0.001; Table). Integrative mutation and gene expression analyses demonstrated that COD subtype was responsive to chemotherapy, whereas INT subtype showed responsiveness to immunotherapy with immune-check point inhibitor (ICI). Tissue microarray analysis showed practical utility of IGF1 and NXPE2 proteins for predicting diffuse type GC’s heterogeneity.Table: 155P
Univariate and multivariate Cox regression analysis of overall survival in diffuse type gastric cancer
Variables | Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
n | HR (95% CI) | P-value | n | HR (95% CI) | P-value | |
Age | 402 | 1.013 (1.001 - 1.025) | 0.037 | 402 | 1.02 (1.007 - 1.032) | 0.003 |
Gender (Male or Female) | 402 | 1.074 (0.805 - 1.433) | 0.625 | |||
AJCC Stage (I, II, III or IV) | 402 | 2.516 (2.088 - 3.032) | <0.001 | 2.67 (2.204 - 3.235) | <0.001 | |
Tumour site (cardia, body, antrum or whole) | 402 | 0.985 (0.777 - 1.248) | 0.9 | |||
COD-signature (INT or COD subtypes) | 402 | 1.675 (1.257 - 2.234) | <0.001 | 2.058 (1.53 - 2.766) | <0.001 |
Abbreviations: HR, hazard ratio; CI, confidence interval; INT, intestinal-like; COD, core diffuse type.
Conclusions
The COD-signature represents a promising diagnostic tool for the identification of diffuse type GC patients who would display different clinical behaviours as well as response to chemotherapy or ICI treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Korea Research Institute of Bioscience and Biotechnology Chungnam National University, College of Medicine Seoul National University, Faculty of Medicine.
Funding
Korea Research Institute of Bioscience and Biotechnology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5056 - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
5710 - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey
Presenter: Sonja Levy
Session: Poster Display session 3
Resources:
Abstract
3152 - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
Presenter: Sandra D'Angelo
Session: Poster Display session 3
Resources:
Abstract
5715 - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) – a preliminary report.
Presenter: Sungjune Kim
Session: Poster Display session 3
Resources:
Abstract
2854 - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Presenter: Kalijn Bol
Session: Poster Display session 3
Resources:
Abstract
2928 - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Presenter: Mathilde Saint-Ghislain
Session: Poster Display session 3
Resources:
Abstract
1235 - Incidence and survival of Uveal Melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm
Presenter: Ahmad Alfaar
Session: Poster Display session 3
Resources:
Abstract
3615 - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Presenter: Evalyn Mulder
Session: Poster Display session 3
Resources:
Abstract
1793 - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program
Presenter: Angelina Tjokrowidjaja
Session: Poster Display session 3
Resources:
Abstract
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract